Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation. The research team are investigating whether lipid profiles can predict adverse maternal and neonatal outcomes.
Full description
The purpose of this research is to investigate whether lipids profiles during pregnancy impact LGA and other adverse outcomes in pregnancy. Participants will have blood drawn twice; the first blood work is a fasting blood draw (separate blood draw) on the same day but preceding the standard glucose test. The second blood draw is drawn at the time of routine clinical care (third trimester blood work).
Patients will be approached at the time of the anatomy ultrasound for participation. If they consent to participate they will have a FASTING lipid panel drawn at the time of their 24-28w GCT and again at the time of their 36w third trimester labs. Patients will receive a reminder call prior to scheduled 24-28 week appointment for fasting instructions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Singleton pregnancy
- Ages 18-45
- Presentation to prenatal care by the 2nd trimester
- Prenatal care at Mount Sinai Hospital
- Anticipated delivery at Mount Sinai Hospital
Exclusion criteria
- Multiple gestations
- Preexisting hyperlipidemia
- Preexisting diabetes
- Delayed presentation to prenatal care after the 2nd trimester 5. Prenatal care or delivery outside of Mount Sinai Health System
Trial design
111 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Nico Tavella
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal